Here is the paradox at the centre of BC’s life sciences ambition: a founder spends years developing a diagnostic tool in a Burnaby lab, secures CE marking in Europe, and lands hospital contracts in Germany and the Netherlands—only to struggle to secure a meeting with Fraser Health.
This is not a one-off frustration. It is a structural pattern playing out across Metro Vancouver's 60-plus commercial-stage life sciences companies. While the sector has grown steadily under the provincial strategy, it is hitting a wall that policy has yet to dismantle: health authority procurement.
Why the home market remains closed
BC’s health authorities operate under procurement frameworks designed for scale, compliance, and risk minimization. This results in a reliance on long-established supplier relationships, multi-year master supply agreements, and a preference for vendors with extensive clinical track records in comparable health systems.
These criteria are intended to protect patient safety, but they create a catch-22 for early-stage companies: you need a reference site to win a contract, and you need a contract to build a reference site. Consequently, BC founders routinely seek their first institutional customers in the United States, Germany, or the United Kingdom—markets with structured pathways for health innovation procurement—before attempting to re-enter their home province.
Canada ranks near the bottom of its OECD peers for domestic health innovation adoption rates, a chronic issue that federal advocacy bodies including BIOTECanada have flagged in submissions to Ottawa. BC is not unique in this dysfunction, but it is particularly exposed given the size and ambition of its life sciences cluster.
The strategy and the gap
The BC Life Sciences Strategy, launched in April 2023 with a $75-million provincial commitment, set out to accelerate the sector across four pillars: talent, capital, infrastructure, and market access. Three years in, the first three pillars are showing measurable progress. Market access, however, remains the point where strategy and reality diverge.
The current framework lacks a binding mechanism to prioritize local suppliers. There is no mandated local consideration in health authority RFP processes, nor is there a structured innovation procurement stream equivalent to the programs piloted in Ontario or the United Kingdom’s National Health Service.
What founders are doing instead
Several Vancouver-area life sciences companies now structure their go-to-market sequencing around international validation, treating BC as a later-stage market rather than a launch pad. This is a workaround for a system that does not yet prioritize domestic innovation.
Investor calculus is shifting to match this reality. Venture investors evaluating BC life sciences deals now stress-test whether a company’s commercialization plan depends on provincial health authority adoption. Companies that have already de-risked by landing US or European contracts are considered more fundable, creating a perverse incentive to build away from home.
The opportunity gap
Precise figures on how much BC health authorities spend annually with non-domestic suppliers on products that have local equivalents are not publicly broken out in a way that allows direct comparison. Health Shared Services BC publishes aggregate procurement data but does not segment by supplier geography. This data gap hinders the ability to build a policy case for intervention.
Even a modest shift in sourcing toward domestic suppliers—in diagnostics, digital health, and medical devices—would represent tens of millions of dollars in addressable revenue for local companies and a material improvement in the risk profile of early-stage investments.
A path forward
Advocates inside Life Sciences BC and across the sector have proposed three specific changes: a formal innovation procurement pathway for commercial-stage companies to access pilot contracts; a domestic supplier consideration requirement in RFP scoring; and public reporting on the share of procurement going to BC-based suppliers to ensure accountability.
These measures do not require compromising on clinical standards. They require treating local procurement as a strategic policy tool, similar to approaches taken in other Canadian provinces and European jurisdictions.
BC has made a $75-million bet that life sciences is a pillar of its economic future. That investment is undermined if the province’s own institutions remain structurally closed to the companies it aims to foster. The fix is a political choice: determining whether the BC Life Sciences Strategy is a branding exercise or a genuine commitment to building a self-reinforcing ecosystem.
